DPAM
BMRN icon

Degroof Petercam Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Degroof Petercam Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$367K Hold
4,200
– – ﹤0.01% 535
2023
Q4 		$405K Buy
+4,200
New +$372K 0.01% 518

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Degroof Petercam Asset Management's BMRN Position: Q1 2024 in Review

Degroof Petercam Asset Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q1 2024 at 4,200 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #535.

Degroof Petercam Asset Management first reported a position in BMRN in Q4 2023 and has held it in 2 quarters since. The position peaked at $405K in Q4 2023. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • Degroof Petercam Asset Management held 4,200 shares of BioMarin Pharmaceuticals worth $367K as of Q1 2024.
  • Degroof Petercam Asset Management left its BioMarin Pharmaceuticals share count unchanged in Q1 2024.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Degroof Petercam Asset Management's portfolio in Q1 2024, its #535 holding.
  • Degroof Petercam Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2023 and has held it in 2 quarters since.
  • Degroof Petercam Asset Management's BioMarin Pharmaceuticals position peaked at $405K in Q4 2023.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Degroof Petercam Asset Management's 13F filing for Q1 2024, filed 13 May 2024.